Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
ADMA Biologics
ADMA
ADMA Biologics
Concentrated Plasma Reliance Will Strain Operations Yet Spark Opportunity
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
02 May 25
Updated
16 Aug 25
2
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$19.24
11.7% undervalued
intrinsic discount
16 Aug
US$16.99
Loading
1Y
-3.2%
7D
2.8%
Author's Valuation
US$19.2
11.7% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$19.2
11.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-74m
856m
2014
2017
2020
2023
2025
2026
2028
Revenue US$855.7m
Earnings US$319.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
20.61%
Biotech revenue growth rate
13.11%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$319.74m
Earnings '28
x
18.75x
PE Ratio '28
=
US$6.00b
Market Cap '28
US$6.00b
Market Cap '28
/
256.08m
No. shares '28
=
US$23.41
Share Price '28
US$23.41
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$19.23
Fair Value '25
